Chapter 4 – Prevention-Chemoprophylaxis regimen: Canadian recommendations for the prevention and treatment of malaria

An Advisory Committee Statement (ACS) from the
Committee to Advise on Tropical Medicine and Travel (CATMAT)


The Committee to Advise on Tropical Medicine and Travel (CATMAT) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to tropical infectious disease and health risks associated with international travel. PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and medical practices, and is disseminating this document for information purposes to both travellers and the medical community caring for travellers.

Persons administering or using drugs, vaccines, or other products should also be aware of the contents of the product monograph(s) or other similarly approved standards or instructions for use. Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) or other similarly approved standards or instructions for use by the licensed manufacturer(s). Manufacturers have sought approval and provided evidence as to the safety and efficacy of their products only when used in accordance with the product monographs or other similarly approved standards or instructions for use.

Chapter 4: Prevention— chemoprophylaxis regimens

Malaria is a severe life-threatening illness. Even with modern, effective treatments and intensive care support, the case-fatality rate for severe infections of Plasmodium falciparum can be as high as 20%. Thus, prevention of disease is the mainstay of reducing its impact on travellers. A variety of interventions exists to reduce this threat. Chief among these is the use of malaria chemoprophylaxis (see Chapters 5 and 8) along with personal protective measures (PPM) against insect bitesReference 1 (see Chapter 3).

Anti-malaral drugs

Most people who take antimalarial chemoprophylaxis will have no or only minor adverse reactionsReference 2, Reference 3, Reference 4, Reference 5, Reference 6, Reference 7, Reference 8. Nevertheless, antimalarial drugs should be prescribed only after completion of an individual risk assessment (see Chapter 2) that takes into consideration the risks and benefits of chemoprophylaxis. In deciding between the various options, the health care provider should consider: the traveller’s health status; other medications being taken; malaria drug effectiveness; risks for and character of adverse drug reactions; and the traveller’s preferences and risk tolerances.

If adverse events do occur, they can have a significant impact on the traveller’s health and on adherence to the medication regimen. One way to test for tolerability is to have a trial of the medication before travelling. To keep adverse effects to a minimum, it is essential that all travellers understand the dosing schedule, including time of day, and whether the chemoprophylaxis should be taken with food, as well as precautions regarding drug-specific side effects (e.g. sun exposure with doxycycline).

The efficacy reported for different antimalarial clinical trials assumes strict adherence to the dosing schedule as well as the use of PPM, such as insect avoidance and use of insect repellents. Some regimens (e.g. mefloquine) are more forgiving of missed doses while some need to be taken on a very regular schedule (e.g. doxycycline) to ensure maximal protection. If travellers are educated on all aspects of malaria prevention and the specific issues around their prophylactic regimen will, they may be more compliant with the treatment schedule.

Selection of antimalarial drugs

Selecting the most appropriate antimalarial chemoprophylaxis involves the health care provider following five steps:

  1. Evaluate the traveller’s exact travel itinerary to determine their malaria risk profile. Ask specific questions about timing, type of travel and destination(s). Once these are determined, the potential antimalarial regimen(s) can be reviewed with the traveller (see Appendix I). For many itineraries, there will be several options. Review the advantages and disadvantages (outlined in Table 8.11), and determine what regimen is the best fit for the individual traveller.
  2. Select the appropriate dosage of the antimalarial agent, taking time to educate the traveller about proper use of the drug (outlined in Table 8.11).
  3. Discuss the importance of PPM, such as insect repellents and bed nets, to help prevent malaria (see Chapter 3).
  4. Discuss the importance of seeking out medical advice urgently if the traveller develops a fever while in a malaria-endemic area or within one yearFootnote a after returning to Canada.

Selection of antimalarial drugs for specific regions of drug resistance

Travellers should know that, while antimalarial medication can markedly decrease the risk of acquiring symptomatic malariaReference 2, Reference 4, Reference 5, Reference 6, Reference 7, Reference 8, Reference 10 chemoprophylaxis does not provide complete protection. PPM complement antimalarialsReference 1 and decrease travellers’ risk of acquiring malaria (see Chapter 3).

Although minor differences in expert opinion exist between jurisdictions (i.e. United States, Europe and Canada), experts do agree that chemoprophylaxis is an essential component of malaria prevention in areas of high transmission. Differences in guidelines often relate to preferred regimens or whether to use chemoprophylaxis in areas with low levels of transmission (see below). Such differences might confuse travellers, and practitioners should therefore take care to explain these differences.

Box 4.1 summarizes the main chemoprophylactic options by resistance status (see Chapter 8 for a more complete discussion of these drugs).

Box 4.1: Malaria chemoprophylaxis options by drug resistance status

Chloroquine-sensitive regions

Chloroquine-sensitive regions are malaria-endemic areas where chloroquine resistance has not been documented or is not widely present. These include Haiti, the Dominican Republic, Central America north of the Panama Canal, parts of Mexico, parts of South America, north Africa, parts of the Middle East, and west/central China. (See individual countries in Appendix I for specific recommendations.)

Drugs of choice: Chloroquine (Aralen®) is the drug of choice for travellers to areas with chloroquine-sensitive malaria. Hydroxychloroquine (Plaquenil®) is an acceptable equivalent alternativeReference 11.

Chloroquine or hydroxychloroquine is taken once a week, beginning at least 1 week before entering a chloroquine-sensitive malaria-endemic region (or 2–3 weeks before to assess tolerability), during the period of exposure, and for 4 weeks after leaving the malaria-endemic region.

Alternatives: Individuals who are unable to tolerate chloroquine or hydroxychloroquine should use atovaquone–proguanil, doxycycline or mefloquine (see next section and Chapter 8).

Chloroquine-resistant regions

Chloroquine-resistant regions are malaria-endemic areas where chloroquine resistance has been documented. Chloroquine-resistant regions include most of sub-Saharan Africa, South America, Oceania and Asia. (See individual countries in Appendix I for specific recommendations.) Note that some border areas of Thailand, Myanmar (Burma), Laos and Cambodia, as well as southern Vietnam, are both chloroquine-resistant and mefloquine-resistant regionsReference 12, Reference 13, Reference 14 (see next section).

There are sufficient data in semi-immune and nonimmune hosts in various geographic locations to conclude that atovaquone–proguanil, doxycycline and mefloquine provide similar levels of protection against chloroquine-resistant malariaReference 2, Reference 4, Reference 5, Reference 6, Reference 7, Reference 8.

Drugs of choice: Atovaquone–proguanil, doxycycline or mefloquineReference 2, Reference 4, Reference 5, Reference 6, Reference 7, Reference 8, Reference 10.

Atovaquone–proguanilis taken daily, beginning at least 1 day before entering a malaria-endemic region (or 3–4 days before to test tolerability), during the period of exposure, and for 1 week after leaving the malaria-endemic regionReference 15.

Doxycycline is taken daily, beginning at least 1 day before entering a malaria-endemic region (or 3–4 days before to test tolerability), during the period of exposure, and for 4 weeks after leaving the malaria-endemic regionReference 4.

Mefloquineis taken weekly, beginning 1 week before entering a malaria-endemic region (or 3 weeks before, to assess tolerability), during the period of exposure, and for 4 weeks after leaving the malaria-endemic regionReference 4.

Alternatives: If atovaquone–proguanil, doxycycline and mefloquine are not well tolerated, primaquine daily can be considered. Begin taking it at least 1 day before entering a malaria-endemic region (or 3–4 days before to ensure tolerability), during the period of exposure, and for 7 days after leaving the malaria-endemic region.

Note: Primaquine is contraindicatedin glucose-6-phosphate dehydrogenase (G6PD) deficiency and contraindicated in pregnancy (see Chapters 5 and 8).

Chloroquine-and mefloquine-resistant regions

Resistance to both chloroquine and mefloquine has been reported in various countries in Asia, Africa and the Amazon basin. However, it has not been found to be a significant problem except in rural, wooded regions where Thailand borders with Myanmar (Burma), CambodiaReference 13, Reference 14 and Laos, as well as in southern Vietnam Reference 12, Reference 16. While these areas are infrequently visited by travellers, use of PPM should be optimized for those travelling there Reference 1.

Drugs of choice: Atovaquone–proguanil or doxycycline (see Chapter 8).

Atovaquone–proguanil is taken daily, beginning at least 1 day before entering a malaria-endemic region or 3–4 days before to ensure tolerability), during the period of exposure, and for 1 week after leaving the malaria-endemic regionReference 15.

Doxycycline is taken daily, beginning at least 1 day before entering a malaria-endemic region (or 3–4 days before to ensure tolerability), during the period of exposure, and for 4 weeks after leaving the malaria-endemic regionReference 4.

Alternatives: There are currently no alternatives for prevention in these regions.

NOTE: There are no approved drugs to prevent malaria in pregnant women or in children weighing less than 5 kg travelling to mefloquine-resistant regions. Atovaquone–proguanil (Malarone®) may be considered for women after the first trimester who cannot avoid travel to mefloquine-resistant areas (e.g. border areas between Thailand and Cambodia/Myanmar) after careful discussion of the benefits and risks (see Chapters 5 and 8)Reference 17, Reference 18.

Primaquine terminal prophylaxis for prevention of relapses of P. Vivax and P. Ovale

P. vivax and P. ovale parasites can persist in the liver and cause relapse 5 years or more after routine chemoprophylaxis has been discontinuedReference 19, Reference 20. Although considered less virulent than falciparum malaria, P. vivax still carries the potential for significant morbidity requiring intensive careReference 21. Since most malaria-endemic areas of the world (except Haiti and the Dominican Republic) have either P. vivax or P. ovale, travellers to these areas have some risk of acquiring relapsing malaria. Primaquine terminal prophylaxis is administered after the traveller has left a malaria-endemic area, usually during or after the post-travel period of chemoprophylaxis. Primaquine decreases the risk of such relapse by acting against the persistent liver stages (hypnozoites) of P. vivax and P. ovale.

Data pertaining to the risk of relapse are limited. One study showed that, of 725 US Army Ranger task force soldiers stationed in Afghanistan, 38 (5.2%) had P. vivax malaria after leaving, yielding an attack rate of 52.4 cases per 1,000 soldiers. Diagnosis was confirmed at a median of 233 days after return from the malaria-endemic regionReference 21. Military personnel, long-term travellers and expatriates are groups that should be considered for terminal prophylaxis if they were in regions with high P. vivax or P. ovale endemicity. Any traveller who returns to Canada with a history of P. vivax or P. ovale diagnosis should also be considered for terminal prophylaxisReference 22.

Primaquine is contraindicated in pregnant women and individuals deficient in G6PD (see Chapter 8 for contraindications and precautions).

Differences in approaches to malaria chemoprophylaxis

Committee to Advise on Tropical Medicine and Travel (CATMAT) reviews all major sources of malaria prevention information, including World Health Organization (WHO)Reference 23, Centers for Disease Control and Prevention (CDC)Reference 24 and the Health Protection Agency Advisory Committee on Malaria Prevention (ACMP)Reference 25. CATMAT also reviews recent research and national and international epidemiological data in order to provide guidelines and recommendations tailored to the Canadian context. Factors that influence recommendations include: drug licensure, Canadian-specific travel patterns and malaria epidemiology, and the anticipated values and preferences of travellers and health care providers.

Some jurisdictions (e.g. United States) have a very low risk tolerance for malaria in returning travellersReference 24, and thus give more weight to chemoprophylaxis. Other jurisdictions (e.g. most European countries) emphasize the potential for drug-adverse effects, and are less likely to recommend chemoprophylaxis in low-risk areas. As well, region-specific recommendations are dynamic; thus, some differences arise as a result of the age of the epidemiologic evidence on which the individual recommendation is based. In these guidelines, CATMAT has tried to balance the need for protection with the potential for adverse effects of chemoprophylaxis. For the most part, CATMAT guidelines are consistent with the WHOReference 23 and the CDC’s Yellow Book: Health Information for International TravelReference 24, although there are still some minor differences.

CATMAT recommends chloroquine for the prevention of malaria in chloroquine-sensitive regions. In chloroquine-resistant regions, CATMAT recommends atovaquone-proguanil, doxycycline or mefloquine as three equivalent options for the prevention of malaria. This is similar to the approach of the CDC. Recommendations on when to start and stop malaria chemoprophylaxis are also consistent among major guidelines, and they also provide the option of emergency standby therapy for travellers who are going to remote areas where they may be unable to access medical assistance within 24 hours (see section on emergency standby treatment for more information).

CATMAT guidelines sometimes differ from WHO and ACMP guidelines with respect to drug recommendations. For example, in chloroquine-sensitive regions ACMP recommends proguanil as an alternative to chloroquine; however, proguanil alone is not available in Canada, and CATMAT, CDC and WHO do not recommend its use. In addition, in areas with low-to-moderate levels of malaria transmission and with chloroquine resistance (e.g. parts of south Asia, southeast Asia, sub-Saharan Africa and South America), WHO and ACMP recommend a combination of chloroquine and proguanil as first-line chemoprophylaxis. However, CATMAT considers chloroquine-proguanil chemoprophylaxis to be significantly less effective compared with atovaquone-proguanil, doxycycline or mefloquineReference 26, Reference 27 and does not recommend this regimen.

Emergency standby therapy for short-term travellers is an option that all the guidelines include, although CATMAT and CDC have more restrictive criteria as to when to use it. CATMAT recommends standby self-treatment for selected travellers who are unable to access medical assistance within 24 hours. CDC guidelines recommend atovaquone-proguanil or artemether-lumefantrine for this use, whereas CATMAT recommends standby malaria treatment with atovaquone-proguanil or quinine and doxycycline, since artemether-lumefantrine is not available in Canada. However, CATMAT does not recommend using mefloquine for therapy under any circumstances because of the high likelihood of severe adverse reactions when using higher therapeutic doses. For more information about self-treatment, see Chapter 7.

Discontinuing antimalarial drugs

Fatal malaria has occurred in travellers who have discontinued an effective antimalarial drug in favour of one that is less protectiveReference 11, Reference 28, Reference 29, Reference 30. During travel, individuals might meet other travellers and/or health care providers who suggest that they change or stop their antimalarial medication. For the most part, such advice should be ignored or questioned; medications used in other areas of the world may be less effective, may be associated with serious adverse effects or may not be manufactured to Canadian standards and are not recommended for Canadian travellers. Examples include proguanil alone (Paludrine®), pyrimethamine (Daraprim®), dapsone-pyrimethamine (Maloprim®) and mefloquine-sulfadoxine-pyrimethamine (Fansimef®).

One of the exceptions to this general rule is when the traveller is suffering significant adverse events associated with the chemoprophylactic agent. In such a situation, and when the advice is provided by a health care provider (preferably the one who provided the initial advice), changing medication is reasonable. Ideally, this would be to another agent recommended by CATMAT in these guidelines. Discontinuation of all chemoprophylaxis is NOT a reasonable option.

Co-administration of antimalarial drugs with vaccines

Travellers requiring antimalarial medications may also require vaccination against agents for which live, oral bacterial vaccines exist. Because such vaccines require bacterial replication to induce a protective immune response, simultaneous administration of antibiotics may interfere with vaccine effectiveness. Doxycycline is an antibiotic and should never be co-administered with live attenuated bacterial oral vaccines. Mefloquine and chloroquine have shown in vitro inhibitory activity against an oral typhoid vaccineReference 31. Proguanil has some antibacterial activity, but co-administering atovaquone-proguanil with live, oral typhoid and cholera vaccines to children did not affect the antibody response to the vaccineReference 32. However, co-administering of proguanil and chloroquine with live, oral typhoid and cholera vaccines decreased vaccine immunogenicityReference 33. Vaccine efficacy studies measuring the impact on the incidence of clinical typhoid and cholera of theco-administration of antimalarials with live, oral typhoid and cholera vaccines have not been performed. Since the data are not definitive, the cautious approach will be to complete vaccination with live oral typhoid or cholera vaccines at least 3 days before the first dose of antimalarial medicationReference 34, Reference 35, Reference 36. Formalin-and/or heat-inactivated oral vaccines (such as Dukoral®) do not contain live bacteria and may be co-administered with antimalarials.

Concurrent use of chloroquine also interferes with the antibody response to intradermal administration of human diploid cell rabies vaccineReference 37. If intradermal rabies vaccine is administered to someone taking chloroquine, rabies serology may help confirm response to vaccination, but it is not always easily available.

During the discussion of chemoprophylaxis:

  1. Tell travellers that malaria can be fatal, but that medications rarely cause serious adverse events if selected and used with care.
  2. Choose a medication that is least likely to exacerbate any past or present medical problem(s).
  3. Present all the options to travellers and, unless there is a contraindication, give them a choice of which chemoprophylaxis they prefer; all recommended first-line malaria chemoprophylactic regimens are equally effective.
  4. Emphasize that medication should be taken in the recommended fashion to minimize significant adverse events.
  5. Discuss the option of a drug trial to check for medication-associated adverse reactions before travelling.
  6. Discuss strategies to change medication if serious adverse effects should arise during travel.
  7. Advise travellers that if a malaria medication is tolerated well they should continue taking it regardless of negative anecdotes about the drug. There is no evidence to suggest that long- term use of currently recommended therapies for travellers will result in additional risks for severe adverse events.
Table 4.1: Evidence-based medicine recommendations
Recommendation EBM Rating

Abbreviation: EBM, evidence-based medicine.

Note: For a description of the categories and quality of evidence of the recommendations, see Appendix IV.

Chloroquine (Aralen®) or hydroxychloroquine (Plaquenil®) is the drug of choice for travellers to areas with chloroquine-sensitive malariaReference 11 A I
Atovaquone–proguanil, doxycycline or mefloquine are drugs of choice for travellers to areas with chloroquine-resistant or mefloquine-sensitive malariaReference 2, Reference 4, Reference 5, Reference 6, Reference 7, Reference 8, Reference 10. A I
Atovaquone–proguanil and doxycycline are drugs of choice for travellers to areas with mefloquine-resistant malariaReference 4, Reference 15, Reference 38. A I
Primaquine is recommended for malaria chemoprophylaxis for travellers to regions with chloroquine resistance who are not willing or able to use atovaquone–proguanil, doxycycline or mefloquineReference 5. A I
Primaquine is recommended as post-travel terminal prophylaxis for travellers who have suffered from Plasmodium vivax or Plasmodium ovale malaria while abroadReference 22. B III
Standby malaria treatment with atovaquone–proguanil or quinine and doxycycline is recommended for travellers who are more than a day away from malaria diagnostic help. C III
Doxycycline is an antibiotic and should never be co-administered with any live, oral bacterial vaccines. Vaccination with live oral typhoid or cholera vaccines should be completed at least 3 days before the first dose of choloroquine, atovaquone–proguanil or mefloquineReference 34, Reference 35, Reference 36. B III
Concurrent use of chloroquine interferes with antibody response to intradermal administration of human diploid cell rabies vaccineReference 37. If intradermal rabies vaccine is administered to someone taking chloroquine, it is recommended that post-vaccine rabies antibodies be obtained to verify an adequate immunologic response. B III


Reference 1

Committee to Advise on Tropical Medicine and Travel. Statement on Personal Protective Measures to Prevent Arthropod Bites. Can Commun Dis Rep 2012;38 (ASC-2):1–18.

Return to reference 1 referrer

Reference 2

Sanchez JL, DeFraites RF, Sharp TW, Hanson RK. Mefloquine or doxycycline prophylaxis in US troops in Somalia. Lancet 1993 Apr 17;341(8851):1021–2.

Return to reference 2 referrer

Reference 3

Koren G, Matsui D, Bailey B. DEET-based insect repellents: safety implications for children and pregnant and lactating women. CMAJ 2003 Aug 5;169(3):209–12.

Return to reference 3 referrer

Reference 4

Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, et al. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997 Jun 15;126(12):963–72.

Return to reference 4 referrer

Reference 5

Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995 Jun;171(6):1569–75.

Return to reference 5 referrer

Reference 6

Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am J Trop Med Hyg 1999 Apr;60(4):521–5.

Return to reference 6 referrer

Reference 7

Shanks GD, Kremsner PG, Sukwa TY, Van Der Berg JD, Shapiro TA, Scott TR, et al. Atovaquone and proguanil hydrochloride for prophylaxis of malaria. J Travel Med 1999;SUPPL 6:S21-S27.

Return to reference 7 referrer

Reference 8

Shanks GD, Gordon DM, Klotz FW, Aleman GM, Oloo AJ, Sadie D, et al. Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin Infect Dis 1998 Sep;27(3):494–9.

Return to reference 8 referrer

Reference 9

Mali S, Kachur SP, Arguin PM. Malaria surveillance—United States, 2010. MMWR Surveill Summ 2012 Mar 2;61(2):1–17.

Return to reference 9 referrer

Reference 10

Lell B, Luckner D, Ndjave M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998 Mar 7;351(9104):709–13.

Return to reference 10 referrer

Reference 11

Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963–2001. Ann Intern Med 2004 Oct 5;141(7):547–55.

Return to reference 11 referrer

Reference 12

Arguin PM, Mali S. Malaria. In: Brunette G.W., Kozarsky PE, Magill AJ, Shlim D.R., Whatley A.D., editors. CDC Health Information for International Travel 2012.New York: Oxford University Press; 2012. p. 223–43.

Return to reference 12 referrer

Reference 13

Wongsrichanalai C, Pickard AL, Wernsdorfer WH, Meshnick SR. Epidemiology of drug-resistant malaria. Lancet Infect Dis 2002 Apr;2(4):209–18.

Return to reference 13 referrer

Reference 14

Wongsrichanalai C, Sirichaisinthop J, Karwacki JJ, Congpuong K, Miller RS, Pang L, et al. Drug resistant malaria on the Thai-Myanmar and Thai-Cambodian borders. Southeast Asian J Trop Med Public Health 2001 Mar;32(1):41–9.

Return to reference 14 referrer

Reference 15

Camus D, Djossou F, Schilthuis HJ, Hogh B, Dutoit E, Malvy D, et al. Atovaquone-proguanil versus chloroquine-proguanil for malaria prophylaxis in nonimmune pediatric travelers: results of an international, randomized, open-label study. Clin Infect Dis 2004 Jun 15;38(12):1716–23.

Return to reference 15 referrer

Reference 16

Kozarsky PE, Arguin PM, Navin A. Malaria. CDC health information for international travel, 2005–2006. Philadelphia: Elsevier Mosby; 2005.

Return to reference 16 referrer

Reference 17

Stauffer WM, Kamat D, Magill AJ. Traveling with infants and children. Part IV: insect avoidance and malaria prevention. J Travel Med 2003 Jul;10(4):225–40.

Return to reference 17 referrer

Reference 18

Na-Bangchang K, Manyando C, Ruengweerayut R, Kioy D, Mulenga M, Miller GB, et al. The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women. Eur J Clin Pharmacol 2005 Sep;61(8):573–82.

Return to reference 18 referrer

Reference 19

Shwartz E, Parise M, Kozarsky P, Cetron M. Delayed onset of malaria-implications for chemoprophylaxis in travellors. N Engl J Med 2003 Oct 16;349(16):1510–6.

Return to reference 19 referrer

Reference 20

Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 2004 Nov;48(11):4075–83.

Return to reference 20 referrer

Reference 21

Kotwal RS, Wenzel RB, Sterling RA, Porter WD, Jordan NN, Petruccelli BP. An outbreak of malaria in US Army Rangers returning from Afghanistan. JAMA 2005 Jan 12;293(2):212–6.

Return to reference 21 referrer

Reference 22

Hill DR, Baire JK, Parise ME, Lewis LS, Ryan ET, Magill AJ. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg 2006;75(3):402–15.

Return to reference 22 referrer

Reference 23

World Health Organization. International travel and health. 2012.

Return to reference 23 referrer

Reference 24

CDC Health Information for International Travel 2012. New York: Oxford University Press; 2012.

Return to reference 24 referrer

Reference 25

Bradley DJ, Bannister B. Guidelines for malaria prevention in travellers from the United Kingdom for 2003. Commun Dis Public Health 2003 Sep;6(3):180–99.

Return to reference 25 referrer

Reference 26

Lobel HO, Miani M, Eng T, Bernard KW, Hightower AW, Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. Lancet 1993 Apr 3;341(8849):848–51.

Return to reference 26 referrer

Reference 27

Steffen R, Fuchs E, Schildknecht J, Naef U, Funk M, Schlagenhauf P, et al. Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet 1993 May 22;341(8856):1299–303.

Return to reference 27 referrer

Reference 28

Humar A, Sharma S, Zoutman D, Kain KC. Fatal falciparum malaria in Canadian travellers. CMAJ 1997 Apr 15;156(8):1165–7.

Return to reference 28 referrer

Reference 29

Kain KC, MacPherson DW, Kelton T, Keystone JS, Mendelson J, MacLean JD. Malaria deaths in visitors to Canada and in Canadian travellers: a case series. CMAJ 2001 Mar 6;164(5):654–9.

Return to reference 29 referrer

Reference 30

Centers for Disease Control and Prevention. Malaria deaths following inappropriate malaria chemoprophylaxis—United States, 2001. MMWR Morb Mortal Wkly Rep 2001 Jul 20;50(28):597–9.

Return to reference 30 referrer

Reference 31

Horowitz H, Carbonaro CA. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 1992 Dec;166(6):1462–4.

Return to reference 31 referrer

Reference 32

Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, et al. Efficacy of atovaquone/ proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. Clin Infect Dis 2002 Nov 15;35(10):1147–54.

Return to reference 32 referrer

Reference 33

Kollaritsch H, Que JU, Kunz C, Wiedermann G, Herzog C, Cryz SJ, Jr. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine. J Infect Dis 1997 Apr;175(4):871–5.

Return to reference 33 referrer

Reference 34

Mefloquine (mefloquine hydrchloride tablets) Product Monograph. 2010.

Return to reference 34 referrer

Reference 35

Malarone Product Monograph. Mississauga: GlaxoSmithKline; 2012.

Return to reference 35 referrer

Reference 36

Aralen Product Monograph. 2008.

Return to reference 36 referrer

Reference 37

Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, Sumner JW, et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986 Jan 30;314(5):280–4.

Return to reference 37 referrer

Reference 38

Krudsood S, Patel SN, Tangpukdee N, Thanachartwet W, Leowattana W, Pornpininworakij K, et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmodium falciparum malaria in Thailand. Am J Trop Med Hyg 2007 Apr;76(4):655–8.

Return to reference 38 referrer


Footnote a

The large majority of travel-related malaria cases diagnosed in non-endemic countries present within several months of return from an endemic areaReference 9. However, some cases, including P. falciparum malaria, will present after a more protracted period, i.e. ≥ 6 months post-exposure. For this reason, CATMAT recommends that travellers who become ill with an unexplained fever within one year of returning home (regardless of whether malaria prophylaxis was prescribed or taken) should seek immediate medical attention and tell the physician their travel history. Particular attention should be paid to fevers developing in the 3 months following travel, the period during which > 90% of P. falciparum-related disease is expressed.

Return to footnote a referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: